STOCK TITAN

Axsome Therapeutics Inc - AXSM STOCK NEWS

Welcome to our dedicated news page for Axsome Therapeutics (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Axsome Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Axsome Therapeutics's position in the market.

Rhea-AI Summary
Axsome Therapeutics, Inc. (AXSM) will host a virtual event on December 7 to update investors on its development programs for solriamfetol, a CNS disorder therapy. The event will feature discussions by physician thought leaders and the Axsome senior leadership team on clinical development plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
conferences
-
Rhea-AI Summary
Axsome Therapeutics, Inc. (AXSM) CEO to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences
-
Rhea-AI Summary
Axsome Therapeutics reports 3Q 2023 financial results with total product revenue of $57.8 million, representing 244% YoY growth. Net product sales for Auvelity® were $37.7 million, a 36% QoQ increase, while net product revenue for Sunosi® was $20.1 million, a 20% YoY growth. The company is on track for important clinical and regulatory milestones in the next 12 months, including NDA submissions and pivotal trial readouts and initiations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
earnings
Rhea-AI Summary
Axsome Therapeutics is participating in the Alzheimer's Foundation of America awareness campaign by lighting its headquarters in teal. The campaign aims to raise awareness of Alzheimer's disease and show support for those affected by the condition. November is recognized as Alzheimer's Disease Awareness Month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
Rhea-AI Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced that its CEO, Dr. Herriot Tabuteau, will participate in two investor conferences in early November. The first conference is the Guggenheim Healthcare Talks | 5th Annual Inflammation & Immunology Conference on Nov. 7, where Dr. Tabuteau will participate in a fireside chat. The second conference is the 2023 Truist Securities BioPharma Symposium on Nov. 8, where Dr. Tabuteau will be part of a panel discussion on Alzheimer's Disease - Palliative Treatments. A live webcast and archive of the Guggenheim event will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
conferences
-
Rhea-AI Summary
Axsome Therapeutics presents positive data from its ACCORD Phase 3 trial of AXS-05 for Alzheimer's disease agitation at CTAD Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
clinical trial
Rhea-AI Summary
Axsome Therapeutics appoints Susan Mahony to its board of directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
management
-
Rhea-AI Summary
Axsome to report Q3 2023 financial results and host conference call on Nov. 6, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
conferences earnings
-
Rhea-AI Summary
Axsome Therapeutics joins global narcolepsy advocacy community to raise awareness of World Narcolepsy Day
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
Rhea-AI Summary
Axsome Therapeutics CEO to participate in investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
conferences
Axsome Therapeutics Inc

Nasdaq:AXSM

AXSM Rankings

AXSM Stock Data

3.78B
34.88M
17.12%
83.03%
15.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About AXSM

axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.